Highlights Incyte Corporation

Stocks

INCY

US45337C1027

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 21/07/2026 am IST			5-day change	1st Jan Change
115.65 ^USD	-1.36%		+1.24%	+17.09%

20/07	Halozyme Therapeutics, Incyte Sign Deal to Develop Subcutaneous Formulations of Blood Cancer Drug	MT
20/07	Goldman Sachs Adjusts Price Target on Incyte to $110 From $100, Maintains Neutral Rating	MT

Highlights

13/07	Incyte Presents Phase 1/2 Multidose Data for Vga039 (Latarcibart) At Isth 2026 Showing Substantial Bleed Reductions in Patients with All Von Willebrand Disease Types	CI
06/07	Incyte Corporation completed the acquisition of Vega Therapeutics, Inc. from Star OpCo, Inc.	CI
26/06	European Medicines Agency Panel Backs Label Expansion for Incyte's Opzelura	MT
26/06	Incyte Receives Positive Chmp Opinion for Opzelura (Ruxolitinib) Cream for Treatment of Moderate Atopic Dermatitis in Adults	CI
13/06	Incyte Announces Updated Clinical Data From Two Phase 1 Studies Evaluating INCA033989 In Patients With MutCALR-Expressing Myeloproliferative Neoplasms	CI
13/06	Incyte Presents Results from Pivotal Phase 3 Frontmind Trial of Tafasitamab Combination At Eha 2026 Plenary	CI
08/06	Incyte To Acquire Vega Therapeutics For Up To $2 Billion	MT
08/06	Incyte Corporation entered into a definitive agreement to acquire Vega Therapeutics, Inc. from Star OpCo, Inc. for $2 billion.	CI
08/06	Incyte to Acquire Star Therapeutics unit Vega; Shares Up Pre-Bell	MT
08/06	Incyte makes $2 billion bet on bleeding disorder drug ahead of Jakafi patent cliff	RE
07/06	Incyte nears up to $2 billion deal for blood disorder biotech Star, FT reports	RE
30/05	Incyte Announces Positive Results from Pivotal Phase 3 Frontmind Trial Evaluating Tafasitamab (Monjuvi/Minjuvi) and Lenalidomide Added to R-Chop Versus R-Chop Alone in Previously Untreated High-Risk Dlbcl and Hgbl	CI
20/05	Incyte, Genesis Molecular AI Expand Artificial Intelligence Drug Discovery Agreement	MT
19/05	Incyte Collaborates With Edison Scientific to Use AI in Drug Discovery	MT
19/05	Incyte and Edison Scientific Enters Strategic Collaboration to Employ Kosmos AI Platform for Research and Development	CI
07/05	Incyte Announces 24-Week Data For Opzelura Cream In Adults With Moderate Atopic Dermatitis	CI
02/05	Incyte Announces Fda Approval of Jakafi Xr Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease	CI
28/04	Incyte beats first-quarter estimates on strong demand for cancer drugs	RE
28/04	Incyte Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
28/04	Incyte's Q1 Non-GAAP Earnings, Revenue Increase	MT
28/04	Earnings Flash (INCY) Incyte Corporation Posts Q1 Adjusted EPS $1.81 per Share, vs. FactSet Est of $1.32	MT
28/04	Earnings Flash (INCY) Incyte Corporation Reports Q1 Revenue $1.27B, vs. FactSet Est of $1.22B	MT
28/04	Incyte Corporation Reaffirms Earnings Guidance for the Fiscal Year 2026	CI
21/04	Incyte Highlights New Phase 3 Tafasitamab Data At the 2026 American Society of Clinical Oncology Annual Meeting	CI
29/03	Incyte Announces New Positive 54-Week Data for Povorcitinib in Hidradenitis Suppurativa	CI